Compugen to Present at H.C. Wainwright Conference Amid Key Clinical Trials
Event summary
- Compugen management to participate in fireside chat on September 14, 2026, at 3:30 PM ET during H.C. Wainwright 28th Annual Global Investment Conference in New York.
- Live webcast available on Compugen's Investor Relations page, with replay accessible post-event.
- Company currently advancing COM701 in ovarian cancer trial and rilvegostomig through AstraZeneca's clinical trials.
- GS-0321 licensed to Gilead, currently in Phase 1 clinical trial conducted by Compugen.
The big picture
Compugen's participation in the H.C. Wainwright conference comes as it navigates multiple clinical-stage programs, including a pivotal ovarian cancer trial and a bispecific antibody partnership with AstraZeneca. The company's AI-driven discovery platform positions it in the rapidly evolving cancer immunotherapy sector, where success in key trials could attract further investment or strategic alliances. The upcoming fireside chat will provide insights into Compugen's pipeline progress and financial strategy amid a competitive biotech landscape.
What we're watching
- Clinical Progress
- How COM701's performance in the MAIA-ovarian trial will impact Compugen's valuation and partnership prospects.
- Strategic Partnerships
- Whether AstraZeneca's advancement of rilvegostomig will lead to additional collaborations or licensing deals.
- Market Positioning
- The pace at which Compugen can differentiate itself in the competitive cancer immunotherapy space.
Related topics